At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 219 enrolled
Drug / intervention
BMS-986036 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes
In Brief
A Phase 2 clinical trial evaluating BMS-986036 and Placebo (Matching with BMS-986036) for Diabetes Mellitus Type 2. Completed, enrolled 219 participants across 16 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus Type 2
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartApr 2014
Primary CompletionSep 2015
Study CompletionMay 2016
TodayJul 2026
First PostedMar 27, 2014
Enrollment StartApr 15, 2014
Primary CompletionSep 22, 2015
Study CompletionMay 17, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.3 years ago
Interventions
BMS-986036biological
Placebo (Matching with BMS-986036)biological